ADMA Biologics, Inc. (ADMA): Gross Profit
$292.76M
Year ended 2025-12-31
$331.47M
Trailing 12 months to 2026-06-30
+102.5%
3-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $292.76M | +33.3% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $219.55M | +146.8% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $88.94M | +152.2% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $35.27M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | $1.17M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$19.07M | n/a | 2022-03-24, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | -$25.21M | n/m | 2019-03-13, From 2018-01-01 |
| 2017-12-31 | -$6.40M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $4.30M | +50.0% | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | $2.87M | +31.9% | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | $2.17M | +108.1% | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | $1.04M | +132.5% | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | $449.1K | -18.9% | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | $553.5K | n/a | 2013-03-06, From 2011-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $292.76M | +33.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $191.00M | +43.2% |
| Repligen Corp (RGEN) | 2025-12-31 | $386.25M | +40.6% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $205.62M | +92.4% |
| Vericel Corp (VCEL) | 2025-12-31 | $205.60M | +19.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $90.32M | +27.5% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.05B | +119.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $799.07M | +1.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.17B | +36.4% |
Compare ADMA, TWST, RGEN, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗